Skip to main content
. 2014 Aug 26;14:465. doi: 10.1186/1471-2334-14-465

Figure 3.

Figure 3

Change from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR in a) the PILLAR study and b) the ASPIRE study.